Provider: Silverchair
Database: AmericanMedicalAssociation
Content: text/plain; charset="UTF-8"

TY  - JOUR
AU  - Caswell-Jin, Jennifer L.
AU  - Kurian, Allison W.
AU  - Plevritis, Sylvia K.
T1  - US Breast Cancer Mortality—Reply
PY  - 2024
Y1  - 2024/04/25
DO  - 10.1001/jama.2024.5482
JO  - JAMA
JA  - JAMA
SN  - 0098-7484
AB  - In Reply Dr Jatoi suggests that a reduction in the incidence of ER-negative breast cancer over the past decades could have contributed to the decline in breast cancer mortality observed in SEER between 1975 and 2019. Indeed, a decline in cancer incidence can have a primary role in decline of cancer-specific mortality, as in the case of lung cancer. Similarly, a change in the composition of molecular subtypes among people diagnosed with incident breast cancer could affect mortality rates and even decrease mortality if the subtype with the higher mortality rate became less prevalent.As Jatoi notes, in our study we did not estimate what proportion of the decline in breast cancer mortality over time was attributable to changes in breast cancer incidence. Our objective was to quantify the relative changes in mortality reduction attributable to screening and treatment interventions while controlling for changes in mortality rates that could be attributed to changes in incidence rates. The CISNET models estimated annual breast cancer age-adjusted mortality rates in the absence and presence of modeled interventions by subtype and by calendar year. The reported 58% reduction in age-adjusted breast cancer mortality in 2019 is relative to the estimated mortality in 2019 had there been no screening or treatment improvements since 1975.
Y2  - 5/20/2024
UR  - https://doi.org/10.1001/jama.2024.5482
ER  -